Perioperative Management of Medications Used in the Treatment of Rheumatoid Arthritis
Patients with rheumatoid arthritis (RA), an inflammatory arthritis that can destroy joint structures, are often on multiple medications to control disease activity. These medications may have significant toxicities and side effects. Over the course of their lifetime, patients with this disease often require orthopedic procedures, including total joint arthroplasty, and the medications they are taking present management issues specific to the perioperative period. As many of these medications are immunosuppressive, the concern for postoperative infection and delayed wound healing are particularly worrisome. We conducted a review of the available literature pertaining to the perioperative use of the most commonly prescribed medications for RA. Although the existing data directly addressing perioperative complications in orthopedic surgery is sparse, information on relevant complications resulting from the general use of these drugs may be used as a basis for conservative recommendations.
Key wordsRheumatoid arthritis perioperative management corticosteroids methotrexate anti-TNF rituximab
The authors would like to thank C. Ronald MacKenzie, MD, for his editorial assistance in preparation of this manuscript.
- 8.Leopold SS, Casnellie MT, Warme WJ, et al (2003) Endogenous cortisol production in response to knee arthroscopy and total knee arthroplasty. J Bone Jt Surg Am Vol 85-A:2163–2167Google Scholar
- 12.Hanssen AD, Cabanela ME, Michet CJ Jr (1987) Hip arthroplasty in patients with systemic lupus erythematosus. J Bone Jt Surg Am Vol 69:807–814Google Scholar
- 23.Hernigou P, Thiery JP, Benoit J et al (1989) Methotrexate diffusion from acrylic cement. Local chemotherapy for bone tumours. J Bone Jt Surg Br 71:804–811Google Scholar
- 41.Law JK, Ho JK, Hoskins PJ, et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089PubMedCrossRefGoogle Scholar